Trials & Filings

Merrimack Fails in Ovarian Cancer Trial

Biomarkers give hope for subset of patients

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Merrimack Pharmaceuticals posted results of a global, Phase II, open-label, randomized study of MM-121 in combination with paclitaxel versus paclitaxel alone in patients with platinum-resistant or platinum-refractory advanced ovarian cancers. This study did not meet the primary endpoint of progression free survival (PFS) in the overall population. The hazard ratio (HR) for PFS was 1.0. Ongoing analysis of a pre-specified set of biomarkers mechanistically linked to ErbB3 signaling identified a p...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters